Compare LICN & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LICN | BTMD |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.3M | 64.4M |
| IPO Year | 2021 | 2021 |
| Metric | LICN | BTMD |
|---|---|---|
| Price | $5.35 | $2.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $2.25 |
| AVG Volume (30 Days) | 63.1K | ★ 336.1K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 722.22 |
| EPS | N/A | ★ 0.74 |
| Revenue | N/A | ★ $192,219,000.00 |
| Revenue This Year | N/A | $2.03 |
| Revenue Next Year | N/A | $6.58 |
| P/E Ratio | ★ N/A | $2.66 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.57 | $1.27 |
| 52 Week High | $8.28 | $4.75 |
| Indicator | LICN | BTMD |
|---|---|---|
| Relative Strength Index (RSI) | 62.45 | 69.28 |
| Support Level | $3.98 | $2.02 |
| Resistance Level | $6.90 | $2.20 |
| Average True Range (ATR) | 0.83 | 0.16 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 61.49 | 96.49 |
Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and sales of financial and taxation training software.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.